Results 181 to 190 of about 7,305,993 (392)

Pompe disease in adulthood: effects of antibody formation on enzyme replacement therapy

Genetics in Medicine, 2016
J. D. de Vries, E. Kuperus, M. Hoogeveen‐Westerveld, M. Kroos, S. Wens, M. Stok, N. A. van der Beek, M. Kruijshaar, D. Rizopoulos, P. Van Doorn, A. T. van der Ploeg, W. Pijnappel   +11 more
semanticscholar   +1 more source

Antibody Formation in Myelomatosis [PDF]

Journal of Clinical Pathology, 1953
openaire   +3 more sources

A DIA‐MS‐based proteomics approach to find potential serum prognostic biomarkers in glioblastoma patients

Molecular Oncology, EarlyView.
A DIA‐MS‐based proteomics analysis of serum samples from GB patients and healthy controls showed that high levels of IL1R2 and low levels of CRTAC1 and HRG in serum are associated with poor survival outcomes for GB patients. These circulating proteins could serve as biomarkers for the prediction of outcome in patients with GB.
Anne Clavreul, François Guillonneau, Odile Blanchet, Hamza Lasla, Audrey Rousseau, Catherine Guette, Alice Boissard, Cécile Henry, Morgan Dhondt, Pascal Jézéquel, Philippe Menei, Jean‐Michel Lemée   +11 more
wiley   +1 more source

Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. [PDF]

BioDrugs, 2021
Bots SJ, Parker CE, Brandse JF, Löwenberg M, Feagan BG, Sandborn WJ, Jairath V, D'Haens G, Vande Casteele N.   +8 more
europepmc   +1 more source

Interferon-gamma inducible protein 10 (IP10) induced cisplatin resistance of HCC after liver transplantation through ER stress signaling pathway. [PDF]

, 2015
Tumor recurrence remains an obstacle after liver surgery, especially in living donor liver transplantation (LDLT) for patients with hepatocellular carcinoma (HCC).
Geng, Wei, Li, Chang-Xian, Ling, Chang-Chun, Liu, Xiao-Bing, Lo, Chung-Mau, Ma, Yuen-Yuen, Man, Kwan, Ng, Kevin TP, Qi, Xiang, Zhai, Yuan   +9 more
core   +1 more source

Studies on the cellular responses to the antigen and their relation to the antibody formation

, 1953
Nobuo Tanaka
openalex   +2 more sources

EGFR‐STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1‐positive prostate cancer

Molecular Oncology, EarlyView.
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva, Bernardo Orr, Ana Azeredo, Andreia Brandão, Manuel R. Teixeira, Paula Paulo   +5 more
wiley   +1 more source

Antibody formation against SARS-CoV-2 in imatinib-treated COVID-19 patients. [PDF]

J Infect, 2022
Morales-Ortega A, Farfán-Sedano AI, Izquierdo-Martínez A, Llarena-Barroso C, Jaenes-Barrios B, Mesa-Plaza N, Toledano-Macías M, Soria Fernández-Llamazares G, Molina-Esteban L, García de Tena J, Prieto-Menchero S, Gonzalo-Pascua S, San Martín-López JV, Bernal-Bello D.   +13 more
europepmc   +1 more source

Less Anti-infliximab Antibody Formation in Paediatric Crohn Patients on Concomitant Immunomodulators

Journal of Pediatric Gastroenterology and Nutrition - JPGN, 2017
H. M. Kansen, P. V. van Rheenen, R. Houwen, W. E. Tjon a Ten, G. Damen, A. Kindermann, J. Escher, V. Wolters   +7 more
semanticscholar   +1 more source

Evaluation and modification of tumor cell isolation techniques from malignant effusions for rapid drug sensitivity testing

Molecular Oncology, EarlyView.
Non‐small cell lung cancer targeted treatment is limited to a few known genetic alterations, with few alternatives in advanced treatment lines. To direct treatment decisions by drug sensitivity testing (DST), this study compared several methods for tumor cell isolation from malignant effusions, pointing to repeated CD45+ cell depletion for effective ...
Navit Mooshayef, Hana Barhom, Sumit Chatterji, Netta Hecht, Oran Warhaftig, Iris Kamer, Oranit Zadok, Jair Bar, Limor Broday, Amir Onn, Michael Peled   +10 more
wiley   +1 more source